Episodes
Friday Jul 28, 2023
Friday Jul 28, 2023
The Kidney Disease: Improving Global Outcomes (KDIGO) guidelines were recently updated with a focus on kidney health in patients with diabetes. The updated guidelines include recommendations on screening, prevention, and treatment of chronic kidney disease (CKD), including the use of SGLT2 inhibitors, finerenone, and ACE inhibitors or ARBs. The written commentary posted on the iForumRx website provides a succinct summary of the Top Ten Things Every Clinician Should Know.
Guest Authors: Kara Olstad, PharmD; Gurminder Sanghera, BSc, PharmD; and Darren Grabe, PharmD
Music by Good Talk
Friday Feb 03, 2023
Friday Feb 03, 2023
Hyperkalemia is a common electrolyte disorder in patients with CKD that can be exacerbated by renin-angiotensin-aldosterone system (RAAS) inhibitors. While hyperkalemia poses potential risks to patients with CKD, the potentially negative impact of discontinuing RAAS inhibitor therapy on long-term renal and cardiovascular outcomes in CKD patients is unclear.
Guest Author: Michelle A. Fravel, PharmD, BCPS
Music by Good Talk
Thursday Oct 13, 2022
Top Ten Things Every Clinician Should Know About the 2022 Heart Failure Guidelines
Thursday Oct 13, 2022
Thursday Oct 13, 2022
The 2022 AHA/ACC/HFSA Heart Failure Guidelines is a much-needed update and consolidates previously published recommendations. In the written commentary we describe the top ten things every clinician should know about the 2022 AHA/ACC/HFSA Heart Failure Guidelines. This podcast episode highlights some of the key recommendations from the guidelines and addresses some of the practical implications.
Guest Authors: Madison Yates, PharmD and Megan Supple, PharmD, BCACP, CPP
Music by Good Talk
Wednesday Jun 08, 2022
The Top Ten Things Every Clinician Should Know About Sacubitril/Valsartan
Wednesday Jun 08, 2022
Wednesday Jun 08, 2022
Sacubitril/valsartan is considered part of the backbone of guideline-recommended therapies for the management of patients with heart failure. In 2021, sacubitril/valsartan became the preferred treatment over an ACEi or ARB in patients with heart failure with reduced ejection fraction (HFrEF) because it reduces the risk of cardiovascular death and hospitalization for heart failure in nearly all adult patients with chronic heart failure. All clinicians should be familiar with the indications, dosing, safety, and monitoring of sacubitril/valsartan. Affordability, access, and inappropriate dose titration remain major barriers to achieving optimal outcomes.
Guest Authors: Jessica Wooster, PharmD, BCACP and Elizabeth Yett, PharmD, BCACP
Special Guest: Dustin (DJ) Clark, PharmD, BCACP
Music by: Good Talk
Tuesday Mar 01, 2022
Extra Protection? Finerenone Use in Patients with Type 2 DM and CKD
Tuesday Mar 01, 2022
Tuesday Mar 01, 2022
Despite prevention efforts, about 1 in 3 patients diagnosed with diabetes have comorbid CKD. Half of these individuals have moderate to severe disease. Unlike patients with type 1 diabetes where it develops after many years after the diagnosis, CKD is commonly present at diagnosis in patients with type 2 diabetes. While many interventions are available to prevent the progression of CKD, more are needed.
Guest Authors: Katherine Montag Schafer, PharmD, BCACP, CDCES and Kyle Hunt, MD
Music by Good Talk
Monday Jun 10, 2019
If Your Heart’s Not into It, Do You Really Need to Take Your Meds?
Monday Jun 10, 2019
Monday Jun 10, 2019
Dilated cardiomyopathy is the leading cause of sudden cardiac death and heart failure (HF) and the chief indication for cardiac transplantation. However, approximately 40% of patients see a significant improvement in left ventricular ejection fraction and reduction in the left ventricle size over time with pharmacologic treatment. As deprescribing becomes an increasingly important part of our clinical practice, we need more data about how deprescribing impacts outcomes, particularly in chronic diseases such as heart failure. The recently published TRED-HF is attempted to address this important question: Is the burden of lifelong therapy with medications necessary or worth it in patients with "recovered" dilated cardiomyopathy?
Guest Author: Jennifer Pruskowski, PharmD, BCPS, BCGP, CPE
Music by Good Talk
Friday Feb 24, 2017
Friday Feb 24, 2017
Hypertension affects more than 70% of patients with type 2 diabetes mellitus and further increases the risk of cardiovascular disease in this high-risk population. While renin angiotensin system (RAS) blockers are clearly indicated in patients with heart failure, chronic kidney disease with proteinuria, and coronary artery disease (CAD), experts have come to different conclusions regarding their role as initial antihypertensive therapy for patients with diabetes.
Theme Music by Good Talk
Sunday May 17, 2015
Co-trimoxazole+RAAS Inhibitors: A Deadly Combination?
Sunday May 17, 2015
Sunday May 17, 2015
Could a commonly prescribed antibiotic, when combined with a renin-angiotensin system inhibitor, lead to sudden death?